Rigel Pharmaceuticals Inc. (NASDAQ: RIGL)
$11.23
+0.6400 ( +6.04% ) 150.7K
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Market Data
Open
$11.23
Previous close
$10.59
Volume
150.7K
Market cap
$197.53M
Day range
$10.64 - $11.36
52 week range
$7.12 - $17.30
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | May 07, 2024 |
8-k | 8K-related | 13 | Apr 12, 2024 |
ars | Annual reports | 1 | Apr 10, 2024 |
def | Proxies and info statements | 41 | Apr 10, 2024 |
3 | Insider transactions | 2 | Mar 29, 2024 |
4 | Insider transactions | 1 | Mar 29, 2024 |
pre | Proxies and info statements | 39 | Mar 29, 2024 |
8-k | 8K-related | 16 | Mar 05, 2024 |
10-k | Annual reports | 101 | Mar 05, 2024 |
4 | Insider transactions | 1 | Mar 01, 2024 |